Drugs / BIW-8962
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00775502 | Oct 2008 → May 2011 | plasma cell myeloma | Kyowa Kirin, Inc. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01898156 | Jul 2013 → Jun 2016 | small cell lung carcinoma | Kyowa Kirin Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIW-8962 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01898156 ↗ |
| Action | Deplete | “This study will test the ability of a specially designed monoclonal antibody to destroy multiple myeloma cells.” NCT00775502 ↗ |
| Modality | Monoclonal antibody | “BIW-8962 is a monoclonal antibody which targets the GM-2 ganglioside” NCT00775502 ↗ |
| Route | Intravenous | “Intravenous administration of liquid dosage form.” NCT00775502 ↗ |